Document Type : Research Articles
Authors
1
Department of Biochemistry and Molecular Biology, National Hepatology and Tropical Medicine Research Institute, Cairo University, Cairo, Egypt.
2
Department of Endemic Medicine and Hepato-gastroenterology, Faculty of Medicine, Cairo University, Cairo, Egypt.
3
Department of Surgery, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
4
Department of Internal Medicine, Ahmed Maher Teaching Hospital, Cairo, Egypt.
5
Clinical Oncology Department, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK), Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt.
6
Tropical Medicine Department, El Sahel teaching hospital, Cairo, Egypt.
Abstract
Introduction: Adiponectin is anti-inflammatory and anti-tumor cytokine secreted exclusively from adipocytes. There
is a growing evidence of association between adiponectin gene polymorphism and development of pancreatic cancer.
The current study aimed at evaluation of the possible association between selected adiponectin gene polymorphism and
the risk of pancreatic cancer. Methods: Prospective case-control study included 77 patients (29 women and 48 men)
with biopsy-proven pancreatic adenocarcinoma and 97 healthy control. Blood samples from all included participants
were genotyped for 3 single nucleotide polymorphism (SNPs) of adiponectin genes (rs1501299C>A, rs266729C>G and
rs2241766G>T) by PCR. Clinical, biochemical, and radiological data analyzed. Results: We demonstrated a significant
association between the three studied SNPs (rs1501299, rs266729, and rs2241766) and increased risk of pancreatic
adenocarcinoma (p<0.001). Furthermore, in clinical correlation analysis, Patients with rs2241766 polymorphism
have a lower frequency of lymph node involvement (p 0.05). Smoking and older age were independent predictors of
pancreatic adenocarcinoma. Conclusion: We provided evidence that variants in adiponectin gene might influence the
development and progression of pancreatic cancer.
Keywords
Main Subjects
)